• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals

Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.
Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a spin-off of the Vrije Universiteit Brussel (VUB) and VIB, is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.
For its first European base, pharmaceutical consultant Amador Bioscience has chosen to set up shop in Limburg province, Belgium. The company, which already had branches in the United States and China, was attracted to Hasselt because of the proximity of the University of Hasselt (UHasselt), which has a strong reputation in biostatistics. In the coming years, Amador Bioscience is looking to hire 120 biostatisticians and biomedical engineers at its Belgian site.
It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
Belgium is home to one of the world’s strongest health clusters and has long been ranked as the best country in the EU for clinical trials. However, if Belgium is to maintain this attractive clinical trial environment – and its quality healthcare system – the country needs to improve its position regarding the reuse of health data for research. BioVox spoke with Ingrid Maes from Inovigate about an upcoming report on Belgium’s real-world data initiatives and legislation, and how the country compares with the rest of Europe.
Knowledge for Growth is Belgium’s largest life sciences conference, and with a mix of thought leaders from across the ecosystem, always has a finger on the pulse of current topics. This year, the event focused heavily on data science, with a range of keynote talks and sessions dedicated to the important topic. One of the afternoon panels in particular, Understanding Data, held a lot of insights from Liesbet Peeters (Prof. Biomedical Data Sciences at Hasselt University) and Bart Vannieuwenhuyse (Data Sciences Lead at Janssen Benelux Campus).
Things are moving fast for Flamingo Therapeutics, a Leuven-based biotech company developing innovative RNA-targeted cancer therapies. The start-up is a pioneer in the field of lncRNAs, a large and untapped class of disease-causing targets within the so-called ‘dark matter’ of the human genome.
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.
Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a spin-off of the Vrije Universiteit Brussel (VUB) and VIB, is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.
For its first European base, pharmaceutical consultant Amador Bioscience has chosen to set up shop in Limburg province, Belgium. The company, which already had branches in the United States and China, was attracted to Hasselt because of the proximity of the University of Hasselt (UHasselt), which has a strong reputation in biostatistics. In the coming years, Amador Bioscience is looking to hire 120 biostatisticians and biomedical engineers at its Belgian site.
It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
Belgium is home to one of the world’s strongest health clusters and has long been ranked as the best country in the EU for clinical trials. However, if Belgium is to maintain this attractive clinical trial environment – and its quality healthcare system – the country needs to improve its position regarding the reuse of health data for research. BioVox spoke with Ingrid Maes from Inovigate about an upcoming report on Belgium’s real-world data initiatives and legislation, and how the country compares with the rest of Europe.
Knowledge for Growth is Belgium’s largest life sciences conference, and with a mix of thought leaders from across the ecosystem, always has a finger on the pulse of current topics. This year, the event focused heavily on data science, with a range of keynote talks and sessions dedicated to the important topic. One of the afternoon panels in particular, Understanding Data, held a lot of insights from Liesbet Peeters (Prof. Biomedical Data Sciences at Hasselt University) and Bart Vannieuwenhuyse (Data Sciences Lead at Janssen Benelux Campus).
Things are moving fast for Flamingo Therapeutics, a Leuven-based biotech company developing innovative RNA-targeted cancer therapies. The start-up is a pioneer in the field of lncRNAs, a large and untapped class of disease-causing targets within the so-called ‘dark matter’ of the human genome.